SVNT - NEWS POSTS - COULD BE HUGE

Source - http://tinyurl.com/775482w

Pegloticase (Krystexxa) Kidney Disease and Dialysis 30-Jan-12 11:01 pm I am very positive about Pegloticase, believe that it is going to be one of the major drugs in the market for cure of KIDNEY DISASE addition to chronic gout and also thinking that it will be a major solution for DIALYSIS., am buying as much as possible since it was $2.20.

Here is article

PHILADELPHIA -- November 14, 2011 -- In patients with refractory chronic gout and stage 3 and 4 chronic kidney disease (CKD), treatment with pegloticase for up to 6 months has no deleterious renal effects, researchers said here November 10 at the American Society of Nephrology (ASN) Kidney Week 2011.

Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase was developed to fulfil this need.

“Pegloticase was developed for the treatment of chronic disabling gout that is refractory to conventional urate-lowering therapy,” said Marsha Wolfson, MD, Savient Pharmaceuticals, East Brunswick, New Jersey. “Our results showed that therapy with pegloticase for up to 6 months in patients with stages 3 and 4 chronic kidney disease is efficacious and has no adverse renal effects.”

For the study, researchers evaluated data from 2 duplicate phase 3 clinical trials comparing pegloticase with placebo.

They analysed data from 103 patients with stage 3 or 4 CKD (49% of the entire cohort). Patients were treated with pegloticase 8 mg every 2 weeks (n = 42), pegloticase 8 mg every 4 weeks (n = 41), or placebo (n = 20).

Using estimated glomerular filtration rate (eGFR), researchers assessed renal function at weeks 0, 7, 13, 19, and 25 post randomisation in these patients using the 4-variable modification of diet in renal disease (MDRD) formula. At week 0, mean eGFR in patients treated every 2 weeks and every 4 weeks was 40 mL/min/1.73 m2, compared with 43 mL/min/1.73 m2 in those treated with placebo. At week 25, eGFR was 42 mL/min/1.73 m2 in those treated every 2 weeks, and 41 mL/min/1.73 m2 in those treated every 4 weeks, compared with 47 mL/min/1.73 m2 in those treated with placebo at 47 mL/min/1.73 m2.

Changes in eGFR over time were not differentially affected by treatment (P =.28), and no discontinuation pattern was seen. The most common adverse events included gout flare and infusion reaction. Funding for this study was provided by Savient Pharmaceuticals Inc. [Presentation title: Effect of Pegloticase (PGL) on Renal Function in Patients With Chronic Kidney Disease (CKD).